At the time of writing, RAPT Therapeutics Inc [RAPT] stock is trading at $29.4, down -0.27%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RAPT shares have gain 4.00% over the last week, with a monthly amount glided 17.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
RAPT Therapeutics Inc [NASDAQ: RAPT] stock has seen the most recent analyst activity on October 27, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $70. Previously, JP Morgan upgraded its rating to Overweight on October 20, 2025, and kept the price target unchanged to $55. On October 13, 2025, Barclays initiated with a Overweight rating and assigned a price target of $35 on the stock. Leerink Partners upgraded its rating to a Outperform but stick to its price target of $37 on September 26, 2025. JP Morgan upgraded its rating to a Neutral but $14 remained the price target by the analyst firm on July 30, 2025. In a note dated December 26, 2024, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $10.
For the past year, the stock price of RAPT Therapeutics Inc fluctuated between $5.67 and $42.39. Currently, Wall Street analysts expect the stock to reach $49.17 within the next 12 months. RAPT Therapeutics Inc [NASDAQ: RAPT] shares were valued at $29.4 at the most recent close of the market. An investor can expect a potential return of 67.24% based on the average RAPT price forecast.
Analyzing the RAPT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.62 and Total Capital is -0.74. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.98 points at the first support level, and at 28.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.86, and for the 2nd resistance point, it is at 30.32.
Ratios To Look Out For
It is important to note that RAPT Therapeutics Inc [NASDAQ:RAPT] has a current ratio of 12.04. As well, the Quick Ratio is 12.04, while the Cash Ratio is 2.84.
